top
Search terms
Results 11 - 20 of 43 - ordered by :
Pages: 1 2 3 4 5
Escardio

In clinical trials - where the sickest patients are often excluded - mortality rate is as low as 5%. Other drugs groups include beta-blockers, ACE inhibitors, and statins develeoped to lower ...

Date : 01/09/2009
Escardio

[...]both over-consumption of calories and reduced physical activity are involved in childhood obesity. [...]in early childhood, overweight and obesity are associated with the classical risk factors ...

Date : 31/08/2009
Escardio

Type of healthcare reimbursement system influences the achievement of cholesterol targets, reveals research presented at ESC Congress 2013 today by Dr Anselm Kai Gitt from Germany. Dr Gitt said: ...

Date : 31/08/2013
Escardio

After providing blood samples and measurements of their blood pressure, height, weight and waist circumference, participants each wore an activity monitor on their thigh for 24 hours a day over a ...

Date : 31/07/2015
Escardio

Renowned expert, Professor Eugene Braunwald (Brigham and Women’s Hospital and Harvard Medical School, Boston, USA) speaks to ESC Congress News about the options. “LDL-C is the principal ...

Date : 27/08/2017
Escardio

Very high levels of high-density lipoprotein (HDL or “good”) cholesterol may be associated with an increased risk of heart attack and death, according to research presented today at ESC ...

Date : 25/08/2018
Escardio

The intermediate-risk population was made up of participants without cardiovascular disease, including men ≥55 and women ≥60 years old with risk factors such as smoking, early renal dysfunction ...

Date : 30/08/2017
Escardio

Doctors must emphasise importance of complying with treatment say researchers Thousands of statin users worldwide are suffering preventable heart attacks, simply because they are not complying with ...

Date : 07/12/2006
Escardio

Experts from the European Society of Cardiology (ESC) will present a special programme.1 “Lifestyle changes appear to be responsible for falls in blood cholesterol in the general populations of ...

Date : 03/11/2017
Escardio

Inclisiran—an investigational drug that “switches off” PCSK9 synthesis in the liver—lowers rates of low-density lipoprotein (LDL) cholesterol for up to one year in patients ...

Date : 29/08/2017